Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 34Active not recruiting 19Not yet recruiting 15Completed 11Terminated 4Unknown 3Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4Thoracic 2Gastrointestinal 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × trastuzumab deruxtecan × Breast × Clear all
NCT05744375 2026-04-02

TRANSCENDER

Spanish Breast Cancer Research Group

Phase 2 Terminated
2 enrolled 10 charts
Breast

Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Daiichi Sankyo

Phase 2 Terminated
253 enrolled 21 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06231693 2025-05-08

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

AstraZeneca

Terminated
2 enrolled
Breast

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡